Cognition Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $44.00K.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $65.00K, a 282.35% increase year-over-year.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $17.00K.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $65.00K.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $71.00K, a 13.41% decline from fiscal 2024.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $82.00K.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.62M, a 486.23% increase from fiscal 2021.
- Cognition Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $276.00K, a 2023.08% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $44.00K 10-Q · filed 2026-08-07 | |
| 2025-12-31 | $71.00K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $65.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $82.00K 10-K · filed 2025-03-20 | |
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $65.00K 10-Q · filed 2025-11-06 | |
| 2022-12-31 | $1.62M 10-K · filed 2024-03-26 | |
| 2022-09-30 | $1.27M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $22.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $303.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $276.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $5.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $34.00K 10-Q · filed 2021-11-17 | |
| 2021-03-31 | $14.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $13.00K 10-K · filed 2022-03-30 | |
| 2020-06-30 | $11.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |